{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:33:43Z","timestamp":1776404023179,"version":"3.51.2"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["R01 DK97830"],"award-info":[{"award-number":["R01 DK97830"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["P30 DK19525"],"award-info":[{"award-number":["P30 DK19525"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["LEI23H0"],"award-info":[{"award-number":["LEI23H0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RICKEL19A0-1"],"award-info":[{"award-number":["RICKEL19A0-1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jctejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical & Translational Endocrinology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jcte.2025.100392","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T14:35:53Z","timestamp":1744122953000},"page":"100392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis"],"prefix":"10.1016","volume":"40","author":[{"given":"Wang Shin","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XianYan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanicia","family":"Daley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Rickels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3 Pt 2","key":"10.1016\/j.jcte.2025.100392_b0005","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1164\/ajrccm\/151.3_Pt_2.S47","article-title":"\u201cThe cystic fibrosis transmembrane conductance regulator gene","volume":"151","author":"Tsui","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcte.2025.100392_b0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"\u201cThe extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcte.2025.100392_b0015","series-title":"Cystic Fibrosis Foundation Patient Registry,\u201c in \u201d2022 Annual Data Report","author":"Foundation","year":"2022"},{"key":"10.1016\/j.jcte.2025.100392_b0020","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.2147\/DMSO.S191091","article-title":"\u201cType 1 diabetes and bone fragility: links and risks","volume":"12","author":"Starup-Linde","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.jcte.2025.100392_b0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13300-020-00964-1","article-title":"\u201cDiabetes and bone fragility","volume":"12","author":"Romero-D\u00edaz","year":"2021","journal-title":"Diabetes Ther"},{"issue":"11","key":"10.1016\/j.jcte.2025.100392_b0030","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jdiacomp.2018.08.016","article-title":"\u201cDeterminants of fracture in adults with type 1 diabetes in the USA: Results from the T1D exchange clinic registry","volume":"32","author":"Dhaliwal","year":"2018","journal-title":"J Diabetes Complications"},{"issue":"1","key":"10.1016\/j.jcte.2025.100392_b0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2265.2012.04484.x","article-title":"\u201cThe impact of dysglycaemia on bone mineral accrual in young people with cystic fibrosis","volume":"78","author":"Rana","year":"2013","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.jcte.2025.100392_b0040","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2019.01.004","article-title":"Markers of bone turnover are reduced in patients with CF related diabetes; the role of glucose","volume":"18","author":"Mathiesen","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcte.2025.100392_b0045","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.3390\/cells9092073","article-title":"\u201cOsteoblast-osteoclast communication and bone homeostasis","volume":"9","author":"Kim","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jcte.2025.100392_b0050","first-page":"1017","article-title":"\u201cOsteoporosis: pathophysiology and therapeutic options","volume":"19","author":"F\u00f6ger-Samwald","year":"2020","journal-title":"EXCLI J"},{"key":"10.1016\/j.jcte.2025.100392_b0055","doi-asserted-by":"crossref","unstructured":"S. L. Wilson-Barnes, S. A. Lanham-New, and H. Lambert, \u201cModifiable risk factors for bone health & fragility fractures,\u201d Best Practice & Research Clinical Rheumatology, p. 101758, 2022, DOI: 10.1016\/j.berh.2022.101758.","DOI":"10.1016\/j.berh.2022.101758"},{"key":"10.1016\/j.jcte.2025.100392_b0060","article-title":"Bone metabolism and incretin hormones following glucose ingestion in young adults with pancreatic insufficient cystic fibrosis","volume":"30","author":"Lei","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.jcte.2025.100392_b0065","article-title":"\u201cBone resorption and incretin hormones following glucose ingestion in healthy emerging adults","volume":"31","author":"Lei","year":"2023","journal-title":"J Clin Transl Endocrinol"},{"issue":"5","key":"10.1016\/j.jcte.2025.100392_b0070","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1210\/jc.2018-00176","article-title":"Bone turnover markers in patients with nonalcoholic fatty liver disease and\/or type 2 diabetes during oral glucose and isoglycemic intravenous glucose","volume":"103","author":"Maagensen","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcte.2025.100392_b0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bone.2017.01.027","article-title":"Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects","volume":"97","author":"Westberg-Rasmussen","year":"2017","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.jcte.2025.100392_b0080","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1359\/jbmr.2003.18.12.2180","article-title":"\u201cRole of gastrointestinal hormones in postprandial reduction of bone resorption","volume":"18","author":"Henriksen","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.jcte.2025.100392_b0085","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1210\/jc.2019-00008","article-title":"Separate and combined Effects of GIP and GLP-1 infusions on bone metabolism in overweight men without diabetes","volume":"104","author":"Bergmann","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jcte.2025.100392_b0090","doi-asserted-by":"crossref","first-page":"E550","DOI":"10.1152\/ajpendo.00326.2004","article-title":"\u201cHuman duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP","volume":"290","author":"Theodorakis","year":"2006","journal-title":"Am J Phys Endocrinol Metab"},{"key":"10.1016\/j.jcte.2025.100392_b0095","doi-asserted-by":"crossref","unstructured":"T. Edholm et al., \u201cDifferential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis,\u201d (in eng), Neurogastroenterol Motil, vol. 22, no. 11, pp. 1191-200, e315, 2010, doi: 10.1111\/j.1365-2982.2010.01554.x.","DOI":"10.1111\/j.1365-2982.2010.01554.x"},{"issue":"1\u20132","key":"10.1016\/j.jcte.2025.100392_b0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"\u201cGIP and GLP-1, the two incretin hormones: Similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jcte.2025.100392_b0105","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/519784","article-title":"\u201cBone: incretin hormones perceiver or receiver?","volume":"2012","author":"Dicembrini","year":"2012","journal-title":"Exp Diabetes Res"},{"issue":"2","key":"10.1016\/j.jcte.2025.100392_b0110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.14310\/horm.2002.1405","article-title":"Incretins and bone: Evolving concepts in nutrient-dependent regulation of bone turnover","volume":"12","author":"Yavropoulou","year":"2013","journal-title":"Hormones"},{"issue":"1","key":"10.1016\/j.jcte.2025.100392_b0115","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/JOE-17-0278","article-title":"\u201cNovel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists","volume":"236","author":"Mabilleau","year":"2018","journal-title":"J Endocrinol"},{"key":"10.1016\/j.jcte.2025.100392_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110523","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-\u03baB and MAPK pathways via GLP-1R","volume":"130","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jcte.2025.100392_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00122","article-title":"\u201cThe interplay between bone and glucose metabolism","volume":"11","author":"Cipriani","year":"2020","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.jcte.2025.100392_b0130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jcf.2019.01.010","article-title":"\u201cIncretin dysfunction and hyperglycemia in cystic fibrosis: Role of acyl-ghrelin","volume":"18","author":"Sun","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcte.2025.100392_b0135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"\u201cIslet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.jcte.2025.100392_b0140","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.2337\/db22-0399","article-title":"\u201cEffects of GLP-1 and GIP on Islet function in glucose-intolerant, pancreatic-insufficient cystic fibrosis","volume":"71","author":"Nyirjesy","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.jcte.2025.100392_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115079","article-title":"\u201cGIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH(2)","volume":"130","author":"Gasbjerg","year":"2020","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.jcte.2025.100392_b0150","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10209","article-title":"A pilot study showing acute inhibitory effect of GLP-1 on the bone resorption marker CTX in humans","volume":"3","author":"Nissen","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.jcte.2025.100392_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116065","article-title":"\u201cSubcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study","volume":"152","author":"Skov-Jeppesen","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.jcte.2025.100392_b0160","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"\u201cDiagnosis of Cystic Fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181s","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"7","key":"10.1016\/j.jcte.2025.100392_b0165","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/pedi.12700","article-title":"\u201c\u03b2-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose \u2265155\u2009mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"10.1016\/j.jcte.2025.100392_b0170","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"\u201cThe influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.jcte.2025.100392_b0175","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2337\/db11-1451","article-title":"\u201cXenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes","volume":"61","author":"Wice","year":"2012","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.jcte.2025.100392_b0180","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"\u201cIncretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.jcte.2025.100392_b0185","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1210\/clinem\/dgab365","article-title":"\u201cEffect of sitagliptin on islet function in pancreatic insufficient cystic fibrosis with abnormal glucose tolerance","volume":"106","author":"Kelly","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jcte.2025.100392_b0190","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvac004","article-title":"GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells","volume":"188","author":"Hansen","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.jcte.2025.100392_b0195","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1210\/jc.2017-01949","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia","volume":"103","author":"Christensen","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.jcte.2025.100392_b0200","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa097","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes","volume":"4","author":"Christensen","year":"2020","journal-title":"J Endocr Soc"},{"issue":"11","key":"10.1016\/j.jcte.2025.100392_b0205","doi-asserted-by":"crossref","first-page":"E2325","DOI":"10.1210\/jc.2014-2547","article-title":"Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans","volume":"99","author":"Nissen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.jcte.2025.100392_b0210","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/jbmr.4308","article-title":"\u201cThe Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism-A Randomized Crossover Study","volume":"36","author":"Skov-Jeppesen","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.jcte.2025.100392_b0215","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1210\/en.2007-1292","article-title":"\u201cThe murine glucagon-like peptide-1 receptor is essential for control of bone resorption","volume":"149","author":"Yamada","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.jcte.2025.100392_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115553","article-title":"The role of endogenous GIP and GLP-1 in postprandial bone homeostasis","volume":"140","author":"Helsted","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.jcte.2025.100392_b0225","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.763646","article-title":"\u201cLiraglutide inhibits osteoclastogenesis and improves bone loss by downregulating trem2 in female Type 1 diabetic mice: Findings from transcriptomics","volume":"12","author":"Yu","year":"2021","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.jcte.2025.100392_b0230","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.med.0000436191.87727.ec","article-title":"\u201cCystic fibrosis-related bone disease: insights into a growing problem","volume":"20","author":"Stalvey","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"10.1016\/j.jcte.2025.100392_b0235","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jcf.2022.08.011","article-title":"\u201cEvaluation of an association between RANKL and OPG with bone disease in people with cystic fibrosis","volume":"22","author":"Abid","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcte.2025.100392_b0240","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3361309","article-title":"\u201cEffects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: A 52-week clinical study","volume":"2021","author":"Cai","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jcte.2025.100392_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.697442","article-title":"The impact of glucagon-like peptide 1 receptor agonists on bone metabolism and its possible mechanisms in osteoporosis treatment","volume":"12","author":"Xie","year":"2021","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jcte.2025.100392_b0250","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/pr.108.000604","article-title":"\u201cThe role of incretins in glucose homeostasis and diabetes treatment","volume":"60","author":"Kim","year":"2008","journal-title":"Pharmacol Rev"},{"issue":"5","key":"10.1016\/j.jcte.2025.100392_b0255","doi-asserted-by":"crossref","first-page":"E735","DOI":"10.1152\/ajpendo.00159.2005","article-title":"\u201cIs insulin an anabolic agent in bone? Dissecting the diabetic bone for clues","volume":"289","author":"Thrailkill","year":"2005","journal-title":"Am J Phys Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jcte.2025.100392_b0260","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4239\/wjd.v5.i1.14","article-title":"\u201cInsulin and bone: Recent developments","volume":"5","author":"Klein","year":"2014","journal-title":"World J Diabetes"},{"key":"10.1016\/j.jcte.2025.100392_b0265","article-title":"\u201cDiabetes risk factors and bone microarchitecture as assessed by high-resolution peripheral quantitative computed tomography in adults with long-standing type 1 diabetes","author":"Sinha Gregory","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcte.2025.100392_b0270","article-title":"\u201cHyperglycaemia, diabetes and risk of fragility fractures: observational and Mendelian randomisation studies","author":"Emanuelsson","year":"2023","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.jcte.2025.100392_b0275","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10389","article-title":"\u201cAcute hyperinsulinemia alters bone turnover in women and men with type 1 diabetes","volume":"4","author":"Sherk","year":"2020","journal-title":"JBMR Plus"},{"issue":"1","key":"10.1016\/j.jcte.2025.100392_b0280","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1210\/clinem\/dgad431","article-title":"Signs of a glucose- and insulin-independent gut-bone axis and aberrant bone homeostasis in type 1 diabetes","volume":"109","author":"Hartmann","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcte.2025.100392_b0285","doi-asserted-by":"crossref","unstructured":"Q. Tan et al., \u201cRecent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes,\u201d (in eng), Front Endocrinol (Lausanne), vol. 13, p. 838410, 2022, doi: 10.3389\/fendo.2022.838410.","DOI":"10.3389\/fendo.2022.838410"},{"key":"10.1016\/j.jcte.2025.100392_b0290","doi-asserted-by":"crossref","unstructured":"J. Y. Wang et al., \u201cGLP-1 receptor agonists for the treatment of obesity: Role as a promising approach,\u201d (in eng), Front Endocrinol (Lausanne), vol. 14, p. 1085799, 2023, doi: 10.3389\/fendo.2023.1085799.","DOI":"10.3389\/fendo.2023.1085799"},{"issue":"1","key":"10.1016\/j.jcte.2025.100392_b0295","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.jcte.2025.100392_b0300","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s40200-021-00899-9","article-title":"\u201cEfficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists","volume":"20","author":"Okamoto","year":"2021","journal-title":"J Diabetes Metab Disord"},{"issue":"11","key":"10.1016\/j.jcte.2025.100392_b0305","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"\u201cOnce-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcte.2025.100392_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170197","article-title":"GIP and the gut-bone axis \u2013 physiological, pathophysiological and potential therapeutic implications","volume":"125","author":"Stensen","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.jcte.2025.100392_b0315","doi-asserted-by":"crossref","unstructured":"H. Kitaura et al., \u201cEffects of Incretin-Related Diabetes Drugs on Bone Formation and Bone Resorption,\u201d (in eng), Int J Mol Sci, vol. 22, no. 12, 2021, doi: 10.3390\/ijms22126578.","DOI":"10.3390\/ijms22126578"},{"issue":"2","key":"10.1016\/j.jcte.2025.100392_b0320","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-022-00973-1","article-title":"\u201cOlder women who are overweight or obese have vertebral abnormalities, partially degraded TBS, and BMD that worsen with weight loss","volume":"111","author":"Amariti","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"10.1016\/j.jcte.2025.100392_b0325","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10817","article-title":"Effects of incretin therapy on skeletal health in type 2 diabetes\u2014A systematic review","volume":"7","author":"Viggers","year":"2023","journal-title":"JBMR Plus"},{"issue":"6","key":"10.1016\/j.jcte.2025.100392_b0330","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3892\/br.2016.798","article-title":"\u201cAttenuation by incretins of thyroid hormone-stimulated osteocalcin synthesis in osteoblasts","volume":"5","author":"Kainuma","year":"2016","journal-title":"Biomed Rep"},{"issue":"2","key":"10.1016\/j.jcte.2025.100392_b0335","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/path.4655","article-title":"\u201cIncretin actions and consequences of incretin-based therapies: lessons from complementary animal models","volume":"238","author":"Renner","year":"2016","journal-title":"J Pathol"}],"container-title":["Journal of Clinical & Translational Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623725000109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623725000109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T14:27:31Z","timestamp":1762612051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214623725000109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":67,"alternative-id":["S2214623725000109"],"URL":"https:\/\/doi.org\/10.1016\/j.jcte.2025.100392","relation":{},"ISSN":["2214-6237"],"issn-type":[{"value":"2214-6237","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical & Translational Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcte.2025.100392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100392"}}